The crisis caused by the coronavirus pandemic has affected every facet of society, including business law. Our experts have been writing blog posts relating to the impact of the coronavirus since the start of the crisis.
8.5.2020
C&S Coronavirus Blogs – 12 Posts on the Business Law Implications of the Pandemic
Tags
The posts cover subjects ranging from mergers and acquisitions, general meetings and marketing to securing business continuity, solvency and financing. We have also put together summaries of the legislative changes that have been enacted during the spring.
Will the Coronavirus Put Globalisation into Reverse?
Checklist for Transactions in the Age of Coronavirus
Several Temporary Amendments to Employment Law Provide Relief in Covid Crisis
Coronavirus Pulls the Rug from under General Meeting Season
Open Dialogue Is the Key to Weathering a Financing Crisis
Finnish Tax Administration’s Support for Companies during the Pandemic
Covid-19 – Changes to Insolvency Laws Give Distressed Companies Breathing Room
Tools for Successful Procurements during Exceptional Circumstances
Coronavirus Checklist for Corporate Financing Agreements
What Would the Emergency Powers Act Mean for Life Insurance Policies?
Capitalising on Fear Prohibited in Marketing
Coronavirus – Secure Your Business-Critical Issues
Corona Task Force
As our client you have access to the C&S Corona Task Force, which is made up of our experts in coronavirus issues in numerous fields of law. For more information, contact your responsible lawyer to contact the service directly through coronataskforce@castren.fi.
Latest news
Latest references
Pharmaca Health Intelligence – Acquisition of PODIUM Connect and PODIUM Visits businesses
We assisted Pharmaca Health Intelligence in its acquisition of Mediaattori Ltd’s PODIUM Connect® and PODIUM Visits businesses. Through the acquisition, Pharmaca Health Intelligence strengthens its extensive service offerings in medical information, data-driven management, and education for both healthcare and pharmaceutical companies. Pharmaca Health Intelligence is a pioneer in digital medical information and a reliable partner for wellbeing services counties, the private healthcare sector and pharmacies. The company invests in the development of technology and service solutions related to pharmaceutical information, also on an international scale.
Case published 5.12.2024
Gasum – Acquisition of Hærup Biogas
We advised Gasum Oy in its acquisition of 100% of the shares in Hærup Biogas ApS, which owns and operates a biogas plant in the northern part of mainland Denmark. This acquisition marks Gasum’s first biogas plant in Denmark, expanding its biogas production portfolio. Gasum’s strategic goal is to bring seven terawatt hours of renewable gas to the Nordic market yearly by 2027. The acquisition is one step towards achieving the strategic goal. Gasum is a Nordic gas sector and energy market expert. Gasum offers cleaner energy and energy market expert services for industry and for combined heat and power production as well as cleaner fuel solutions for road and maritime transport. The company helps its customers to reduce their own carbon footprint as well as that of their customers.
Case published 3.12.2024
Helkama-Autokauppa – Acquisition of Škoda Dealerships in Helsinki and Tampere
We are advising Helkama-Autokauppa Oy in the acquisition of the Škoda dealerships in Helsinki and Tampere from Hedin Automotive Finland. The transaction is subject to regulatory approval. Helkama-Autokauppa Oy operates as an independent dealer in the dealer network of Helkama-Auto Oy, the Finnish importer of Škoda cars, spare parts and accessories.
Case published 3.12.2024
Huhtamaki – EUR 450 million sustainability-linked syndicated revolving credit facility
We advised Huhtamaki Oyj in relation to a EUR 450 million sustainability-linked syndicated multi-currency revolving credit facility loan agreement (“RCF”) with a maturity of five years. The RCF refinances an existing EUR 400 million sustainability-linked syndicated revolving credit facility signed in January 2021 and will be used for general corporate purposes of the Group. The RCF has two one-year extension options at the discretion of the lenders. The Mandated Lead Arrangers and Bookrunners of the RCF are Citi, Nordea Bank Abp, Skandinaviska Enskilda Banken AB (publ), BNP Paribas, Commerzbank Aktiengesellschaft, Danske Bank A/S, DBS Bank Ltd., London Branch, J.P. Morgan SE, Landesbank Hessen-Thüringen Girozentrale, OP Corporate Bank plc, Raiffeisen Bank International AG and Standard Chartered Bank AG.
Case published 28.11.2024